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Introduction
In 2018, approximately two million people worldwide were 
diagnosed with lung cancer, accounting for 11.6% of the total 
cancer incidence. The death toll from lung cancer was 1.76 
million, accounting for 18.4% of all cancer deaths, and lung 
cancer remains the most common cause of cancer death to 
date1. Eighty-five percent of lung cancers are non-small cell 
lung cancer (NSCLC), more than 50% demonstrate distant 
metastasis at the time of diagnosis of lung cancer, and only 
20% to 25% are identified at an operable stage. 
In those who cannot be operated on, treatment options in-
clude chemotherapy, targeted therapy, and immunotherapy. 
Anti–programmed cell death protein 1 (PD-1) inhibitors (e.g., 
nivolumab and pembrolizumab) and anti–programmed 
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death-ligand 1 (PD-L1) inhibitors (e.g., atezolimumab) are 
approved for the treatment of advanced unresectable mela-
noma and NSCLC. Objective response rate (ORR) with these 
options are 40% to 45% for first-line therapy in melanoma and 
20% for second-line therapy in NSCLC patients who failed to 
show benefit with chemotherapy2-6. Patients who relapsed af-
ter first- or second-generation epidermal growth factor recep-
tor (EGFR)–tyrosine kinase inhibitor (TKI) treatment should 
perform T790M mutation test to confirm that third-generation 
EGFR-TKI is available7. However, if the third-generation EGFR-
TKI is not available, it is necessary to investigate whether it is 
applicable to the immune check point inhibitor.
Predictive biomarkers of immunosuppressive therapy have 
a method to identify tumor mutation burden (TMB), and 
there is a clinical benefit in the case of high mutational burden 
(≥178 nonsynonymous mutations) in whole-exome sequenc-
ing8. However, the measurement of TMB is expensive, and it 
has the disadvantage in representing intratumor heterogene-
ity, and is not standardized. So, PD-L1 expression measure-
ment methods are widely used instead. 
PD-L1 expression constitutes a potential predictive bio-
marker for the selection of PD-1/PD-L1 inhibitors. The corre-
lation between PD-L1 expression level and the clinical efficacy 
of immunotherapy is well-known2,4,9,10. In 2015, the Food and 
Drug Administration (FDA) approved a “companion diag-
nostic” method using the 22C3 clone for pembrolizumab and 
a “complementary diagnostic” method using the 28-8 clone 
for nivolumab. More recently, a “complementary diagnostic” 
test for atezolimumab was also approved. Because of this one 
drug/one diagnostic test co-development method, the cutoff 
values for significant results vary among the different tests 
and for different conditions. For example, the overall response 
rate of nivolumab is 16.7% in squamous cell carcinoma and 
17.6% in nonsquamous NSCLC when a 5% cutoff is employed 
with the PD-L1 immunohistochemistry (IHC) SP263 assay10. 
Separately, in the case of pembrolizumab, a 50% cutoff in the 
PD-L1 IHC 22C3 pharmDx assay showed an ORR of 19.4%4. 
Regarding atezolimumab, 1% or more in tumor cell and 5% or 
more in tumor infiltrating immune cell staining in the PD-L1 
IHC SP142 assay in the immune cells, and is established with 
an ORR of 15%11.
There have been recent efforts to match these three tests12. 
In the present research, the agreement between the PD-L1 
IHC SP263 assay, the PD-L1 IHC 22C3 pharmDx assay, and 
the PD-L1 IHC SP142 assay were evaluated. We also analyzed 
the clinical significance of PD-L1 expression in EGFR mutant 
NSCLC.
Materials and Methods
1. Patients and materials
We analyzed the results of 230 patients who were (1) patho-
logically confirmed to have NSCLC; (2) tested using the PD-L1 
IHC 22C3, SP263, and SP142 methods; (3) evaluated for pep-
tide nucleic acid (PNA) clamping method to confirm EGFR 
mutation; and (4) provided informed consent to undergo PD-
L1 and EGFR mutation testing. All data were gathered in ac-
cordance with the amended Declaration of Helsinki, following 
approval of the study by an independent hospital Institutional 
Review Board (approval no. 3-2018-0260). The need for writ-
ten informed consent was waived because of the retrospective 
design of the study.
2. PD-L1 IHC 
The PD-L1 assay when performed in Korea employs three 
test methods, as follows: the VENTANA PD-L1 (SP263) assay, 
the PD-L1 IHC 22C3 pharmDx assay, and the VENTANA PD-
L1 (SP142) assay. Each test is used as a companion diagnosis 
for nivolumab (Opdivo, Bristol-Myers Squibb, New York, NY, 
USA), pembrolizumab (Keytruda, Merck, Kenilworth, NJ, 
USA), and atezolimumab (Tecentriq, Genentech, San Fran-
cisco, CA, USA), respectively. The combined use of these tests 
is challenging, increasing both social costs and efforts and 
impeding the interpretation of test results. In order to confirm 
consistency, correlation analysis was performed between the 
three PD-L1 test methods. 
Detection and quantification of the proportion of im-
munoreactive tumor cells was performed according to the 
manufacturer’s recommendations. Briefly, neoplastic cells 
were considered positive when cell membrane staining was 
present and negative when cytoplasmic immunoreaction was 
present13. PD-L1 expression was determined using the tumor 
proportion score (TPS), which is the percentage of viable tu-
mor cells showing partial or complete membrane staining14. A 
specimen was considered PD-L1–positive with ≥50% of viable 
tumor cells exhibited membrane staining at any intensity (i.e., 
when TPS ≥50%); conversely, a weak PD-L1–positive result 
was when 1%≤ TPS<50%. In this study, we assigned two cat-
egories according to the TPS 1% cutoffs.
3. EGFR PNA clamping test
A PNA Clamp EGFR Mutation Detection Kit (PANAGENE, 
Inc., Daejeon, Korea) was employed to detect EGFR  muta-
tions by real-time polymerase chain reaction, as previously 
described15. 
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4. Statistical analyses
Clinical characteristics and associations with biomarkers 
were examined by comparing differences using Fisher exact 
test or an independent sample t-test. To evaluate the relation-
ship between PD-L1 expression level ascertained with the 
22C3, SP263, and SP142 assays, the Shapiro–Wilk test was ap-
plied to evaluate the distribution of variability, while the Pear-
son correlation test was used to test relationships between 
two variables. All tests were evaluated on two arms. A p-value 
of less than 0.05 was considered to be significant. Statistical 
analysis was performed using the Statistical Package for the 
Social Sciences version 23 software program (IBM Corp., Ar-
monk, NY, USA). 
Results
1. Patient characteristics
To confirm the clinical features of overexpression of PD-L1 
in Korean patients with NSCLC, we analyzed the results of 230 
patients who were diagnosed with NSCLC and underwent 
both PD-L1 expression test and EGFR  mutation test at two 
hospitals under the jurisdiction of the Yonsei Medical Center. 
The demographic characteristics of the patients are presented 
in Table 1. The median age of the patients was 64.5 (50.8–72.8) 
years, 138 (60.0%) were male, and 124 (53.9%) had a smoking 
history. Histologic types were 194 cases of adenocarcinoma 
(85.1%) and 32 cases of squamous cell carcinoma (14.0%). 
The pathologic stage was stage I in 23 (10.0%), stage II in nine 
(3.9%), stage III in 37 (16.1%), and stage IV in 161 (70.0%). 
EGFR tyrosine kinase domain was detected as wild type in 
164 (71.3%) and EGFR mutant in 66 (28.7%) by PNA clamp-
ing method. The type of EGFR-TKI sensitizing mutation were 
E19del in 33 (50.0%), L858R in 23 (34.8%), and others in 10 
(15.2%), respectively.
2. PD-L1 expressions in 22C3 and SP263 were 
significantly correlated
The VENTANA PD-L1 (SP263) assay was performed in 164 
patients, the PD-L1 IHC 22C3 pharmDx assay was performed 
in 230 patients, and the VENTANA PD-L1 (SP142) assay was 
performed in 53 patients. Of these, 164 patients underwent 
both VENTANA PD-L1 (SP263) assay and PD-L1 IHC 22C3 
pharmDx assay, and the scatter graphs of these two test’s re-
sults are shown in Figure 1. The photographs of PD-L1 IHC 
staining by each method are shown in Figure 2.
Of note, there was a statistically significant higher cor-
relation (rho=0.912; p<0.001, Spearman correlation) in the 
results of 164 patients who underwent both 22C3 and SP263 
tests, and the derived regression equation was as follows: 
22C3=5.578+1.009×SP263 (R=0.920, p<0.001). In our data, 
concordance rate between 22C3 and SP263 assays was 81.6%. 
The VENTANA PD-L1 (SP142) assay, a complement diag-
nosis method for atezolimumab, was approved by the FDA 
in October 2016 and has recently covered by insurance in 
Korea. Therefore, the number of subjects who underwent the 
SP142 test was relatively small in comparison. The correla-
tion of PD-L1 expression values was analyzed in 52 patients 
who performed both 22C3 and SP142 assays. The correla-
tion coefficient (R) was 0.668 (p<0.001) and concordance 
rate was 86.5% between SP142 and 22C3 assays. In addition, 
only 23 patients underwent both SP263 and SP142 tests, the 
correlation coefficient between SP142 and SP263 was −0.105 
(p=0.634). 
There was a significant correlation between 22C3 and 
SP263 assays and between 22C3 and SP263 assays. There-
fore, it is desirable to integrate these test methods. However to 
integrate between SP263 and SP142 assays, it is necessary to 
require additional data to be accumulated.
Table 1. Baseline characteristics 
Variable No. (%) (n=230)
Age, median (Q1–Q3), yr  64.5 (50.8–72.8)
Sex
   Male 138 (60.0)
   Female 92 (40.0)
Smoking history
   Never smoker 106 (46.1)
   Ex-smoker 53 (23.0)
   Current smoker 71 (30.9)
Histologic type
   Adenocarcinoma 194 (85.1)
   Squamous cell carcinoma 32 (14.0)
   Others 2 (0.9)
   Unknown 2 (0.9)
EGFR mutation
   Wild 164 (71.3)
   L858R 23 (10.0)
   E19del 33 (14.3)
   Others 10 (4.3)
Stage
   I 23 (10.0)
   II 9 (3.9)
   III 37 (16.1)
   IV 161 (70.0)
EGFR: epidermal growth factor receptor.
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3. Relationship between EGFR sensitizing mutation and 
PD-L1 expression in NSCLC
According to previous research, patients with NSCLC with 
EGFR-TKI sensitizing mutations are well-known to have 
characteristics of young age, no smoking history, and a lower 
mutation burden versus those with the EGFR  wild type16,17. 
These characteristics were predicted to affect PD-L1 expres-
sion, and we analyzed the effects of EGFR-TKI sensitizing mu-
tation on PD-L1 expression using the 22C3 test. In our data, 
230 patients with NSCLC who underwent PD-L1 IHC 22C3 
pharmDx assay were divided into EGFR wild group and EGFR 
mutant group (Table 2). The clinical features of the EGFR 
mutant group were younger age (62.4±1.16 vs. 66.1±0.78) and 
higher percentage of never smoker (71.2% vs. 36.0%) than the 
EGFR wild group. These clinical characteristics were in good 
agreement with the characteristics of the commonly known 
EGFR mutant NSCLC. The expression of PD-L1 (22C3 phar-
Figure 1. Prevalence and correlation of programmed death-ligand 1 (PD-L1) expression using the 22C3 pharmDx, SP263, and SP142 assays. 
(A) The rate of PD-L1 expression with cutoff tumor proportion score of 1% using the 22C3 pharmDx assay, SP263 assay, and SP142 assay. 
(B) Scatter diagrams illustrating the correlation between expression levels according to 22C3 pharmDx and SP263 assays, 22C3 pharmDx 
and SP142 assays (C), and SP263 and SP142 assays (D). (E) PD-L1 expression by 22C3 assay according to epidermal growth factor receptor 
(EGFR) mutation. IHC: immunohistochemistry; TKI: tyrosine kinase inhibitor.
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mDx assay: TPS ≥1%) was 62.8% (103/164) in EGFR wild type 
and 54.5% (36/66) in EGFR mutant type and there was no dif-
ference in PD-L1 expression according to EGFR-TKI mutation 
(p=0.156).
The clinical features of the NSCLC patients who under-
went 22C3 pharmDx assay divided by PD-L1–negative group 







Age (yr) 66.1±0.78 62.4±1.16 0.012
Sex <0.001
   Male 116 (70.7) 22 (33.3)
   Female 48 (29.3) 44 (66.7)
Smoking history <0.001
   Never smoker 59 (36.0) 47 (71.2)
   Ex-smoker 46 (28.0) 7 (10.6)
   Current smoker 59 (36.0) 12 (18.2)
Histologic type 0.002*
   Adenocarcinoma 130 (80.2) 64 (97.0)
   Squamous cell carcinoma 30 (18.5) 2 (3.0)
   Others 2 (1.2) 0 (0)
Stage 0.133
   I 13 (7.9) 10 (15.2)
   II 7 (4.3)  2 (3.0)
   III 31 (18.9) 6 (9.1)
   IV 113 (68.9) 48 (72.7)
PD-L1 expression (22C3) 0.156
   <1% 61 (37.2)  30 (45.5)
   ≥1% 103 (62.8)  36 (54.5)
Values are presented as mean±SD or number (%).
*Fisher’s exact test.
NSCLC: non-small cell lung cancer; EGFR: epidermal growth factor receptor; TKI: tyrosine kinase inhibitor; PD-L1: programmed death-
ligand 1. 
Figure 2. Programmed death-ligand 1 (PD-L1) immunohistochemical (IHC) staining using the PD-L1 IHC 22C3 pharmDx assay (tumor 
proportion score [TPS] 80%) (A), the PD-L1 IHC SP263 assay (TPS 90%) (B), and the PD-L1 IHC SP142 assay (TC2, 40%; IC0, 0%) (C) (A–C, 
×200).
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(TPS<1%), PD-L1–positive group (TPS≥1%) were shown 
Table 3. There was no significant difference in the clinical 
characteristics (age, sex, smoking status, EGFR mutation) of 
patients according to PD-L1 expression. Therefore, in patients 
with EGFR-TKI sensitizing mutations, PD-L1 expression tests 
should be performed and immunotherapy should be consid-
ered as a treatment for NSCLC.
4. Effect of PD-L1 expression on EGFR-TKI response
The expression of PD-L1 in tumor cells is a defense mecha-
nism against the host immune system and the overexpression 
of PD-L1 is well-known to be a poor prognostic factor18. To 
investigate whether this phenomenon is applicable in patients 
treated with EGFR-TKI, progression-free survival (PFS) and 
overall survival (OS) were analyzed in the context of PD-
L1 expression in 69 patients taking EGFR-TKI. Forty-six of 







No. (%) 91 (39.6) 139 (60.4)
Age, yr 0.276
   <60 29 (32.2) 37 (27.6)
   ≥60 61 (67.8) 97 (72.4)
Sex 0.281
   Male 52 (57.1) 86 (61.9)
   Female 39 (42.9) 53 (38.1)
Smoking history 0.652
   Never smoker 44 (48.4) 62 (44.6)
   Ex-smoker 18 (19.8) 35 (25.2)
   Current smoker 29 (31.9) 42 (30.2)
Smoking status
   Never smoker 44 (48.4) 62 (44.6) 0.336
   Ever smoker 47 (51.6) 77 (55.4)
Histologic type 0.001*
   Adenocarcinoma 84 (92.3) 110 (79.1)
   Squamous cell carcinoma 5 (5.5) 27 (19.4)
   Others 0 (0.0) 2 (1.4)
   Unknown 2 (2.2) 0 (0)
EGFR mutation 0.156
   Wild 61(67.0) 103 (74.1)
   Mutant 30 (33.0) 36 (25.9)
Stage 0.017
   I 13 (14.3) 10 (7.2)
   II 3 (3.3)  6 (4.3)
   III 7 (7.7) 30 (21.6)
   IV 68 (74.7) 93 (66.9)
Stage 0.065
   I 13 (14.3) 10 (7.2)
   ≥II 78 (85.7) 129 (92.8)
*Fisher’s exact test.
NSCLC: non-small cell lung cancer; PD-L1: programmed death-ligand 1; EGFR: epidermal growth factor receptor.
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the patients (66.7%) received first-line treatment. EGFR-TKI 
types were gefitinib in 44 (63.8%), erlotinib in 15 (21.7%), and 
afatinib in 10 (14.5%). The mean OS of patients treated with 
EGFR-TKI was 60.5±6.8 months (95% confidence interval [CI], 
47–74). Separately, the median PFS of patients taking EGFR-
TKI was 10 months (95% CI, 7.7–12) in the PD-L1–negative 
group and 8 months (95% CI, 5.1–11) in the PD-L1–positive 
group (Figure 3C). The mean OS of EGFR-TKI treated patients 
was 69.2±7.8 months (95% CI, 54.0–84.5) in the PD-L1–nega-
tive group and 33.7±3.0 months (95% CI, 28.0–39.5) in the 
PD-L1–positive group (Figure 3D). Thus, PD-L1 expression 
showed poor prognosis and survival but no statistical signifi-
cance (p=0.529 vs. p=0.150). Additionally, the OS was 81.3±8.1 
months in the PD-L1–negative group and 57.2±8.8 months in 
the PD-L1–positive group (Figure 3B), but this was also not 
statistically significant (p=0.202). In conclusion, the expression 
of PD-L1 did not affect the EGFR-TKI response. 
Discussion
In this study, we analyzed the PD-L1 expression and clinical 
characteristics of Korean patients with NSCLC. Of the 230 pa-
tients whose samples were evaluated for PD-L1 using the IHC 
22C3 pharmDx assay, 67 (29.1%) had a PD-L1 TPS of 50% 
or greater and 139 (60.4%) had a PD-L1 TPS of 1% or greater. 
Herbst et al.9 reported that more than 50% of PD-L1 expres-
sion was seen in 28% and that of more than 1% was seen in 
70% of patients, respectively. Reck et al.19 also reported a TPS 
expression of PD-L1 of 50% or more in 30.2% of patients. Thus, 
the prevalence of PD-L1 expression in Korean NSCLC was 
consistent with other findings from previous studies. 
Result of PD-L1 IHC 22C3 pharmDx assay was significantly 
correlated with that of PD-L1 IHC SP263 assay. A blueprint 
project assessed the comparability between 22C3, 28-8, 
SP263, and SP142 and a correlation between three tests ex-
cepting SP142 was verified. The reason for excluding SP142 
Figure 3. Kaplan-Meier curves of progression-free survival (PFS) and overall survival (OS) according to programmed death-ligand 1 (PD-
L1) expression status in non-small cell lung cancer patients. The p-value for the difference between the two curves was determined using the 
log-rank test. (A) PFS for overall population. (B) OS for overall population. (C) PFS for patients treated with epidermal growth factor receptor 
tyrosine kinase inhibitor (EGFR-TKI). (D) OS for patients treated with EGFR-TKI.
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was that it showed weak staining on the tumor cell mem-
brane and fewer positive tumor cells in comparison with 
the other assays12. This study showed a correlation between 
22C3 and SP263 assays and between 22C3 and SP263 assays 
in the real world, so it is desirable to integrate PD-L1 tests. 
Therefore, if one of the three PD-L1 tests is negative, it is nec-
essary to perform the other tests. However, to integrate be-
tween SP263 and SP142 assays, it is required to accumulate 
additional data.
Many previous studies have reported the association of 
PD-L1 expression with EGFR mutation status. Experimental 
results have shown that EGFR  mutation induces PD-L1 ex-
pression20-22. Azuma et al.20 reported that PD-L1 expression 
was significantly higher in patients with clinical features of 
EGFR  mutant NSCLC including female gender, no smok-
ing history, and adenocarcinoma. Separately, Tang et al.23 
indicated that PD-L1 expression was not correlated with sex, 
smoking history, or histopathological type, but was higher in 
EGFR mutants in advanced NSCLC. Zhang et al.24 found that 
PD-L1 expression was not correlated with sex, smoking sta-
tus, or EGFR  mutation in early-stage adenocarcinoma. Our 
results using tissue from NSCLC patients also showed PD-
L1 expression had no association with sex, smoking status, or 
EGFR mutation. 
Because EGFR  mutant NSCLC is expected to have a low 
mutation burden, PD-L1 expression is expected to also be 
lower. However, there was no difference in PD-L1 expression 
in NSCLC according to EGFR  mutation type in our study. 
There are several possible reasons for these different out-
comes. First, Akbay et al.21 and Azuma et al.20 reported that 
PD-L1 expression was higher in the EGFR mutant NSCLC cell 
line and that EGFR-TKI inhibitors reduced PD-L1 expression. 
However, since the human NSCLC cell line has fewer muta-
tion burdens than NSCLC patients, such may infer an inverse 
relationship between EGFR mutation and PD-L1 expression. 
Second, Azuma et al.20 enrolled early-stage NSCLC patients 
who underwent surgical resection; in contrast, most of our 
data included advanced-stage (77.4%) NSCLC patients. This 
difference in stage may have affected the outcome. Third, 
previous studies have employed different methods of IHC 
staining and applied different cutoff values. Tang et al.23 used 
a rabbit monoclonal anti-human antibody (1:200, E1L3N, 
Cell Signaling Technology, Danvers, MA, USA) and applied a 
cutoff value of more than 5% for the H-score. Separately, Ji et 
al.25 incorporated mouse polyclonal antibodies and reagents 
purchased from Abcam, Inc. (Cambridge, UK; i.e., CAT nos. 
ab137132 for anti-PD-1 antibody and ab174838 for anti-PD-
L1 antibody) and their cutoff value was at least 5% of the H-
score. In contrast, our study used PD-L1 expression as a stan-
dardized method for PD-L1 IHC 22C3 pharmDx assay and 
applied a more than 1% expression as a cutoff value.
There were many reports of conflicting results in relation 
to PD-L1 expression and prognosis in NSCLC. Azuma et al.20 
determined that NSCLC patients with high PD-L1 expression 
showed significantly shorter OS than did those with low PD-
L1 expression (median, 55.9 months vs. 72.6 months; p=0.039). 
Lin et al.26 found that PD-L1 expression was associated with a 
good prognosis in lung adenocarcinoma treated with EGFR-
TKI in terms of both PFS and OS (post-TKI PFS: 16.5 months 
vs. 8.6 months; p=0.001 and OS: 35.3 months vs. 19.8 months; 
p=0.004). Although PD-L1 overexpression induces immune 
escape, which is presumed to have a poor prognosis, the re-
sults of this study did not reveal a significant correlation with 
PD-L1 expression and prognosis. In addition, the PD-L1 ex-
pression was not related to the post-TKI recurrence and post-
TKI survival in patients treated with EGFR-TKI. The effect of 
EGFR-TKI on the EGFR signaling pathway might be a major 
factor in lung cancer treatment response. Therefore, the effect 
of PD-L1 expression on the target therapy response would be 
minimal. 
The results of the IHC PD-L1 22C3 and SP263 assays are 
considered to be in good correlation with each other. Since 
PD-L1 expression does not affect the EGFR mutation, it is nec-
essary to perform a PD-L1 test and set the treatment direction 
in patients with EGFR mutant NSCLC.
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